Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine

Leukemia Research

Volumn 31, Issue 2, 2007, Pages 257-259

  Graef, Thorsten ^a   Kuendgen, Andrea ^a   Fenk, Roland ^a   Zohren, Fabian ^a   Haas, Rainer ^a   Kobbe, Guido ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Allogeneic HSCT; AML; Azacitidine; DLI; MDS; Relapse

Indexed keywords

AZACITIDINE; DNA METHYLTRANSFERASE INHIBITOR; FLUDARABINE; LIVER ENZYME;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; BONE MARROW CELL; CASE REPORT; CELL COUNT; CHIMERA; CYTOPENIA; FEMALE; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; TREATMENT OUTCOME; VIRUS REACTIVATION; WORLD HEALTH ORGANIZATION;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; AZACITIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECURRENCE; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33845216261     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.03.003     Document Type: Article

References (8)

1. Kolb H.J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86 5 (1995) 2041-2050
2. de Lima M., Ravandi F., Shahjahan M., Andersson B., Couriel D., Donato M., et al. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 97 5 (2003) 1242-1247
3. Schmid C., Schleuning M., Ledderose G., Tischer J., and Kolb H.J. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23 24 (2005) 5675-5687
4. Wijermans P., Lubbert M., Verhoef G., Bosly A., Ravoet C., Andre M., et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18 5 (2000) 956-962
5. Petti M.C., Mandelli F., Zagonel V., De Gregoris C., Merola M.C., Latagliata R., et al. Pilot study of 5-aza-2′-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 7 Suppl 1 (1993) 36-41
6. Mund C., Hackanson B., Stresemann C., Lubbert M., and Lyko F. Characterization of DNA demethylation effects induced by 5-aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 65 16 (2005) 7086-7090
7. Pinto A., Maio M., Attadia V., Zappacosta S., and Cimino R. Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2′-deoxycytidine. Lancet 2 8407 (1984) 867-868
8. Santourlidis S., Trompeter H.I., Weinhold S., Eisermann B., Meyer K.L., Wernet P., et al. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J Immunol 169 8 (2002) 4253-4261